SGLT2抑制剂对糖尿病患者骨折、截肢的影响(6)
[34]Zinman B,Wanner C,Lachin JM,et al.Empagliflozin, Cardiovascular Outcomes,and Mortality in Type 2 Diabetes[J].New England Journal of Medicine,2015,373(22):2117-2128.[35]Monteiro P,Bergenstal RM,Toural E,et al.Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial[J].Age and Ageing ......
您现在查看是摘要页,全文长 2689 字符。